Published in Drug Alcohol Rev on February 26, 2013
Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies, and barriers in six countries. BMC Health Serv Res (2014) 0.93
The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives. PLoS One (2016) 0.75
Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc (2003) (2017) 0.75
Controlling new drugs under marketing regulations. Addiction (2012) 4.02
What should be done about mephedrone? BMJ (2010) 1.63
Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction (2014) 1.49
Overview of substance use and treatment from Australia. Subst Abus (2014) 1.45
Ketamine : from medicine to misuse. CNS Drugs (2006) 1.30
The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int J Drug Policy (2011) 1.23
Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev (2008) 1.13
High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol (2013) 1.12
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis (2013) 1.09
Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q. Br J Pharmacol (2011) 1.07
Synthesis and biological evaluation of flavan-3-ol derivatives as positive modulators of GABAA receptors. Bioorg Med Chem (2009) 1.07
GABA(C) receptors as drug targets. Curr Drug Targets CNS Neurol Disord (2003) 1.05
The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care (2012) 1.05
Harm reduction healthcare: from an alternative to the mainstream platform? Int J Drug Policy (2010) 1.05
Novel, potent, and selective GABAC antagonists inhibit myopia development and facilitate learning and memory. J Pharmacol Exp Ther (2008) 1.02
Factors affecting the implementation of clinical pharmacy services in China. Qual Health Res (2014) 1.00
Modulation of ionotropic GABA receptors by natural products of plant origin. Adv Pharmacol (2006) 1.00
A molecular basis for agonist and antagonist actions at GABA(C) receptors. Chem Biol Drug Des (2008) 0.95
Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice. Neuropharmacology (2008) 0.90
Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One (2012) 0.90
Legal highs and the challenges for policy makers. Addiction (2010) 0.89
Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships. J Med Chem (2008) 0.88
A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med (2013) 0.88
Potency of GABA at human recombinant GABA(A) receptors expressed in Xenopus oocytes: a mini review. Amino Acids (2013) 0.87
Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abuse Treat (2012) 0.86
Guanidino acids act as rho1 GABA(C) receptor antagonists. Neurochem Res (2009) 0.86
Low nanomolar GABA effects at extrasynaptic α4β1/β3δ GABA(A) receptor subtypes indicate a different binding mode for GABA at these receptors. Biochem Pharmacol (2012) 0.86
Ethnobotany, phytochemistry and pharmacology of the genus Caragana used in traditional Chinese medicine. J Ethnopharmacol (2009) 0.86
3-Hydroxy-2'-methoxy-6-methylflavone: a potent anxiolytic with a unique selectivity profile at GABA(A) receptor subtypes. Biochem Pharmacol (2011) 0.86
Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I. Bioorg Med Chem Lett (2012) 0.85
Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995-2009. AIDS (2011) 0.84
(3-Aminocyclopentyl)methylphosphinic acids: novel GABA(C) receptor antagonists. Neuropharmacology (2006) 0.84
The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction (2010) 0.83
γ-Hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB. J Neurochem (2010) 0.83
Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust (2009) 0.83
6-Methylflavanone, a more efficacious positive allosteric modulator of gamma-aminobutyric acid (GABA) action at human recombinant alpha2beta2gamma2L than at alpha1beta2gamma2L and alpha1beta2 GABA(A) receptors expressed in Xenopus oocytes. Eur J Pharmacol (2005) 0.83
Mutations of the 2' proline in the M2 domain of the human GABAC rho1 subunit alter agonist responses. Neuropharmacology (2004) 0.83
Medicinal chemistry of ρ GABAC receptors. Future Med Chem (2011) 0.82
Flavan-3-ol esters: new agents for exploring modulatory sites on GABA(A) receptors. Br J Pharmacol (2012) 0.82
2'-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors. Br J Pharmacol (2012) 0.82
Differentiating enantioselective actions of GABOB: a possible role for threonine 244 in the binding site of GABA(C) ρ(1) receptors. ACS Chem Neurosci (2012) 0.81
The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochem Res (2009) 0.81
Defining a service for people who use drugs as 'low-threshold': what should be the criteria? Int J Drug Policy (2013) 0.81
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. J Med Chem (2009) 0.80
Ethnopharmacological and bioactivity guided investigation of five TCM anticancer herbs. J Ethnopharmacol (2013) 0.80
Neurochemicals for the investigation of GABA(C) receptors. Neurochem Res (2010) 0.80
Kynurenine Aminotransferases and the Prospects of Inhibitors for the Treatment of Schizophrenia. Curr Med Chem (2015) 0.80
Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemp Clin Trials (2009) 0.79
Flumazenil-independent positive modulation of gamma-aminobutyric acid action by 6-methylflavone at human recombinant alpha1beta2gamma2L and alpha1beta2 GABAA receptors. Eur J Pharmacol (2004) 0.79
Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ1 receptor. ACS Chem Neurosci (2012) 0.78
Metabolomic Approaches to Defining the Role(s) of GABAρ Receptors in the Brain. J Neuroimmune Pharmacol (2015) 0.78
Opioid substitution therapy clients' preferences for targeted versus general primary health-care outlets. Drug Alcohol Rev (2012) 0.77
Buprenorphine use by the smoking route in gaols in NSW. Drug Alcohol Rev (2008) 0.77
Microwave-enhanced synthesis of 2,3,6-trisubstituted pyridazines: application to four-step synthesis of gabazine (SR-95531). Org Biomol Chem (2010) 0.77
Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. J Addict Med (2016) 0.76
Identification of benzopyran-4-one derivatives (isoflavones) as positive modulators of GABA(A) receptors. ChemMedChem (2011) 0.76
Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. Int J Drug Policy (2012) 0.76
Γ-aminobutyric acid(C) (GABAC) selective antagonists derived from the bioisosteric modification of 4-aminocyclopent-1-enecarboxylic acid: amides and hydroxamates. J Med Chem (2013) 0.76
Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Aust N Z J Public Health (2013) 0.76
Why do patients report transferring between methadone and buprenorphine? Drug Alcohol Rev (2009) 0.76
Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, Australia. J Urban Health (2012) 0.76
Self-perceived problem with alcohol use among opioid substitution treatment clients. Addict Behav (2012) 0.76
Where next in ketamine uropathy? Dedicated management centres? BJU Int (2014) 0.75
Stabilization of zwitterions in solution: phosphinic and phosphonic acid GABA analogues. J Phys Chem A (2005) 0.75
Modulation of ionotropic GABA receptors by 6-methoxyflavanone and 6-methoxyflavone. Neurochem Res (2013) 0.75
High risk groups are still not being vaccinated. BMJ (2005) 0.75
Experimental and theoretical charge density distribution in a host-guest system: synthetic terephthaloyl receptor complexed to adipic acid. J Phys Chem A (2012) 0.75
Fitness to practise in pharmacy: a study of impairment in professional practice. Int J Clin Pharm (2012) 0.75
Polysubstance use and misuse or abuse of prescription opioid analgesics: A multi-level analysis of international data. Pain (2017) 0.75
Roadside drug testing would not be much of a deterrent. BMJ (2012) 0.75
A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Aust N Z J Public Health (2011) 0.75
Studies on pyridazine azide cyclisation reactions. Org Biomol Chem (2004) 0.75
Experimental and theoretical charge distribution in (Z)-N-methyl-C-phenylnitrone. Org Biomol Chem (2003) 0.75
Primary healthcare outlets that target injecting drug users: opportunity to make services accessible and acceptable to the target group. Int J Drug Policy (2012) 0.75
The cost of providing primary health-care services from a needle and syringe program: a case study. Drug Alcohol Rev (2012) 0.75
Reply. Pain (2017) 0.75